Evaluation of the effect of Memantine in patients with brain tumors

Phase 3

Recruiting

• Conditions: Cognitive Impairment.; Mild cognitive impairment, so stated; G31.84

• Registration Number: IRCT20211029052903N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Patient with a brain tumor
Candidate for radiotherapy
Satisfaction to participate in the study

Exclusion Criteria

Drug allergy to memantine
History of neurological disorders

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive Impariment. Timepoint: Before and 6 weeks after the start of the intervention. Method of measurement: Mini-Mental State Exam(MMSE).